Progression-free survival (PFS) evaluation defined as the interval from the diagnosis of advanced breast cancer with HER2 positive to disease progression, relapse, death due to any causes or last follow-up. The follow-up interval is 2 years. The gene discussed is ERBB2; the disease is breast carcinoma.